The company has since learned the cyberattack was caused by a third-party contractor’s user session within its cloud-based system being compromised.

Xeltis has reached over 50% enrolment in its US pivotal trial of aXess, a vascular access device designed for adults with end-stage renal disease who require haemodialysis.